Quanterix Seeks FDA Nod for Landmark Alzheimer's Blood Test

BILLERICA, MA – February 03, 2026 – Quanterix Corporation has taken a significant step toward transforming Alzheimer's disease diagnostics, announcing its submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA). The submission is for a novel blood test designed to aid in the detection of brain amyloid plaques, a core pathological hallmark of Alzheimer's disease, in patients experiencing cognitive symptoms.

This non-invasive test represents a potential watershed moment for the millions of individuals and families grappling with the uncertainty of a possible Alzheimer's diagnosis. If cleared by the FDA, the test could provide a widely accessible and less burdensome alternative to current diagnostic methods, such as costly PET scans and invasive lumbar punctures, potentially enabling earlier and more accurate evaluations for a devastating neurodegenerative condition.

The Science of a More Precise Diagnosis

At the heart of the Quanterix submission is a sophisticated multi-analyte algorithmic test that moves beyond the limitations of single-marker diagnostics. Leveraging the company's proprietary Simoa® technology, renowned for its ability to detect proteins at ultra-low concentrations, the test simultaneously measures a panel of five key biomarkers from a single blood sample: p-Tau 217, amyloid-beta 42 (Aβ42), amyloid-beta 40 (Aβ40), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL).

This comprehensive approach is designed to paint a more complete biological picture of the disease. While the ratio of Aβ42 to Aβ40 and the presence of p-Tau 217 are strong indicators of amyloid and tau pathology, respectively, the inclusion of GFAP (a marker of neuroinflammation) and NfL (a general marker of neuronal damage) provides a more nuanced assessment. According to the company, this multi-faceted analysis helps overcome the diagnostic ambiguity that can arise with single-analyte tests, particularly in the early stages of disease where biomarker levels may fall into an inconclusive range.

The submission is not based on speculation; it is supported by robust clinical data from over 1,800 symptomatic patients across three independent cohorts, with findings recently published in the peer-reviewed journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. This evidence underscores the potential of the test to reliably identify patients likely to have amyloid pathology, a critical step in the diagnostic journey.

Navigating a Competitive and Regulated Landscape

Quanterix's journey toward regulatory clearance is bolstered by the test's prior receipt of a Breakthrough Device Designation from the FDA. This program is designed to expedite the review of medical devices that offer a more effective diagnosis for life-threatening or irreversibly debilitating diseases. While this designation provides for more intensive FDA guidance and prioritized review, it does not guarantee a swifter approval. The standard 510(k) review timeline is approximately 90 days, but for novel devices, this can often extend as regulators may request additional information.

The company enters an increasingly competitive but promising field. Other major players are also making significant strides in blood-based Alzheimer's diagnostics. Roche recently secured FDA approval for its Lumipulse test, while C2N Diagnostics' PrecivityAD2 test is already in clinical use. Quanterix aims to differentiate its offering with its five-analyte panel and the extreme sensitivity of its Simoa platform, which it argues provides a more comprehensive and quantitative result for every patient, a key advantage over other methods.

A Paradigm Shift for Patients and Physicians

The potential impact of an accessible, reliable blood test for Alzheimer's cannot be overstated. For decades, the path to diagnosis has been fraught with challenges, often requiring patients to undergo expensive PET imaging or uncomfortable spinal taps to confirm the presence of amyloid plaques. These procedures are not only costly but also limited in their availability, creating significant barriers to care, especially for those in rural or underserved communities.

A simple blood test could democratize Alzheimer's diagnostics, making early and accurate assessment a routine part of primary care for older adults with cognitive concerns. This shift is more critical than ever with the advent of a new class of disease-modifying therapies that can slow the progression of Alzheimer's. These treatments are most effective when administered in the earliest stages of the disease, making timely and accurate detection paramount. An FDA-cleared blood test would be an invaluable tool for identifying patients who could benefit from these new therapies and for monitoring their response to treatment.

This aligns with evolving clinical guidelines. The Alzheimer's Association has already established recommendations for the use of blood-based biomarkers, signaling a readiness within the medical community to integrate these powerful new tools into standard clinical practice once they meet rigorous performance standards.

Quanterix's Strategic Gambit in the Diagnostics Market

This FDA submission is a cornerstone of Quanterix's broader business strategy to establish its technology as a gold standard in clinical diagnostics. The company has long been a leader in the research space, with its Simoa technology cited in thousands of peer-reviewed publications. This move represents a decisive pivot toward the high-stakes clinical diagnostics market.

“The strong execution of the Quanterix team has resulted in this submission, a watershed moment for Quanterix and millions of families seeking clearer answers in the fight against Alzheimer’s disease,” said Mike Miller, Chief Operating Officer of Quanterix, in a press statement. “This filing is the next step in our strategy to establish our technology as a gold standard in clinical diagnostics, offering a scalable solution that bridges the gap between early detection and the emerging class of disease-modifying therapies.”

The company has also been strategically expanding its capabilities. Its 2025 acquisition of Akoya Biosciences, a leader in spatial biology, created a uniquely integrated platform that connects biomarker insights from blood with cellular-level analysis in tissue. This synergy positions Quanterix to support the entire healthcare continuum, from initial discovery research to drug development and, now, routine clinical diagnosis. As the FDA begins its review, the entire healthcare ecosystem—from patients and physicians to competitors and investors—will be watching closely to see if this test can deliver on its promise to bring much-needed clarity to Alzheimer's disease.